MAP2K7 and hepatocellular carcinoma: Co-delivery of sorafenib and the MEK inhibitor AZD6244 by the tumor-targeted nanoparticles prevents the paradoxical activation of ERK and PD-L1 expression and facilitates intra-tumoral infiltration of cytotoxic CD8+ T cells in HCC, resulting in enhanced anti-tumor efficacy